Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 271

1.

Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy.

Renner K, Bruss C, Schnell A, Koehl G, Becker HM, Fante M, Menevse AN, Kauer N, Blazquez R, Hacker L, Decking SM, Bohn T, Faerber S, Evert K, Aigle L, Amslinger S, Landa M, Krijgsman O, Rozeman EA, Brummer C, Siska PJ, Singer K, Pektor S, Miederer M, Peter K, Gottfried E, Herr W, Marchiq I, Pouyssegur J, Roush WR, Ong S, Warren S, Pukrop T, Beckhove P, Lang SA, Bopp T, Blank CU, Cleveland JL, Oefner PJ, Dettmer K, Selby M, Kreutz M.

Cell Rep. 2019 Oct 1;29(1):135-150.e9. doi: 10.1016/j.celrep.2019.08.068.

2.

Long-term follow-up of rituximab in treatment of chronic graft-versus-host disease-single center experience.

Klobuch S, Weber D, Holler B, Edinger M, Herr W, Holler E, Wolff D.

Ann Hematol. 2019 Oct;98(10):2399-2405. doi: 10.1007/s00277-019-03768-x. Epub 2019 Aug 3.

PMID:
31375860
3.

Topical Diclofenac Reprograms Metabolism and Immune Cell Infiltration in Actinic Keratosis.

Singer K, Dettmer K, Unger P, Schönhammer G, Renner K, Peter K, Siska PJ, Berneburg M, Herr W, Oefner PJ, Karrer S, Kreutz M, Datz E.

Front Oncol. 2019 Jul 3;9:605. doi: 10.3389/fonc.2019.00605. eCollection 2019.

4.

Cortical and Commissural Defects Upon HCF-1 Loss in Nkx2.1-Derived Embryonic Neurons and Glia.

Minocha S, Herr W.

Dev Neurobiol. 2019 Jun;79(6):578-595. doi: 10.1002/dneu.22704. Epub 2019 Jun 25.

5.

Effects of continuous high-dose G-CSF administration on hematopoietic stem cell mobilization and telomere length in patients with amyotrophic lateral sclerosis - a pilot study.

Iberl S, Meyer AL, Müller G, Peters S, Johannesen S, Kobor I, Beier F, Brümmendorf TH, Hart C, Schelker R, Herr W, Bogdahn U, Grassinger J.

Cytokine. 2019 Aug;120:192-201. doi: 10.1016/j.cyto.2019.05.003. Epub 2019 May 14.

PMID:
31100684
6.

HCF-2 inhibits cell proliferation and activates differentiation-gene expression programs.

Gudkova D, Dergai O, Praz V, Herr W.

Nucleic Acids Res. 2019 Jun 20;47(11):5792-5808. doi: 10.1093/nar/gkz307.

7.

Correction for Minocha et al., "Rapid Recapitulation of Nonalcoholic Steatohepatitis upon Loss of Host Cell Factor 1 Function in Mouse Hepatocytes".

Minocha S, Villeneuve D, Praz V, Moret C, Lopes M, Pinatel D, Rib L, Guex N, Herr W.

Mol Cell Biol. 2019 Apr 30;39(10). pii: e00127-19. doi: 10.1128/MCB.00127-19. Print 2019 May 15. No abstract available.

8.

A new exon 12 mutation in the EPAS1 gene possibly associated with erythrocytosis.

Schelker RC, Herr W, Grassinger J.

Eur J Haematol. 2019 Jul;103(1):64-66. doi: 10.1111/ejh.13241. Epub 2019 May 16.

PMID:
31038790
9.

Random gene sets in predicting survival of patients with hepatocellular carcinoma.

Itzel T, Spang R, Maass T, Munker S, Roessler S, Ebert MP, Schlitt HJ, Herr W, Evert M, Teufel A.

J Mol Med (Berl). 2019 Jun;97(6):879-888. doi: 10.1007/s00109-019-01764-2. Epub 2019 Apr 17.

PMID:
31001651
10.

Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patients.

Lamby P, Wolff D, Mielke S, Grigoleit GU, Ljungman P, Hilgendorf I, Holler E, Holler B, Weber D, Herr W, Schiltz D, Klein S, Graf S, Bjornhagen-Safwenberg V, Dolderer J, Prantl L.

Ann Hematol. 2019 Aug;98(8):1867-1875. doi: 10.1007/s00277-019-03687-x. Epub 2019 Apr 16.

PMID:
30993415
11.
12.

Dasatinib reduces myelofibrosis by modulating pSTAT5 and NF-κB.

Schelker RC, Andrulis M, Müller G, Ushmorov A, Hart C, Herr W, Vogelhuber M, Iberl S, Grassinger J.

Blood Cells Mol Dis. 2019 May;76:78-81. doi: 10.1016/j.bcmd.2019.02.005. Epub 2019 Feb 20. No abstract available.

PMID:
30827761
13.

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.

Schlenk RF, Weber D, Herr W, Wulf G, Salih HR, Derigs HG, Kuendgen A, Ringhoffer M, Hertenstein B, Martens UM, Grießhammer M, Bernhard H, Krauter J, Girschikofsky M, Wolf D, Lange E, Westermann J, Koller E, Kremers S, Wattad M, Heuser M, Thol F, Göhring G, Haase D, Teleanu V, Gaidzik V, Benner A, Döhner K, Ganser A, Paschka P, Döhner H.

Leukemia. 2019 Aug;33(8):1923-1933. doi: 10.1038/s41375-019-0395-y. Epub 2019 Feb 6.

14.

Detection of hemophagocytic extremely multinucleated giant plasma cells after rituximab/low-dose lenalidomide treatment in CD20+ multiple myeloma.

Schelker RC, Grube M, Reichle A, Wagner B, Herr W, Evert M, Vogelhuber M.

Leuk Lymphoma. 2019 Sep;60(9):2331-2333. doi: 10.1080/10428194.2019.1571200. Epub 2019 Feb 5. No abstract available.

PMID:
30721106
15.

Differential regulation of RNA polymerase III genes during liver regeneration.

Yeganeh M, Praz V, Carmeli C, Villeneuve D, Rib L, Guex N, Herr W, Delorenzi M, Hernandez N; CycliX consortium.

Nucleic Acids Res. 2019 Feb 28;47(4):1786-1796. doi: 10.1093/nar/gky1282.

16.

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.

Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, Kindler T, Lübbert M, Wolf D, Westermann J, Kraemer D, Götze KS, Horst HA, Krauter J, Girschikofsky M, Ringhoffer M, Südhoff T, Held G, Derigs HG, Schroers R, Greil R, Grießhammer M, Lange E, Burchardt A, Martens U, Hertenstein B, Marretta L, Heuser M, Thol F, Gaidzik VI, Herr W, Krzykalla J, Benner A, Döhner K, Ganser A, Paschka P, Döhner H; German-Austrian AML Study Group.

Blood. 2019 Feb 21;133(8):840-851. doi: 10.1182/blood-2018-08-869453. Epub 2018 Dec 18.

PMID:
30563875
17.

Rapid Recapitulation of Nonalcoholic Steatohepatitis upon Loss of Host Cell Factor 1 Function in Mouse Hepatocytes

Minocha S, Villeneuve D, Praz V, Moret C, Lopes M, Pinatel D, Rib L, Guex N, Herr W.

Mol Cell Biol. 2019 Feb 15;39(5). pii: e00405-18. doi: 10.1128/MCB.00405-18. Erratum in: Mol Cell Biol. 2019 Apr 30;39(10):.

18.

Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis.

Heudobler D, Rechenmacher M, Lüke F, Vogelhuber M, Klobuch S, Thomas S, Pukrop T, Hackl C, Herr W, Ghibelli L, Gerner C, Reichle A.

Front Pharmacol. 2018 Nov 28;9:1357. doi: 10.3389/fphar.2018.01357. eCollection 2018. Review.

19.

Biomodulatory Treatment With Azacitidine, All-trans Retinoic Acid and Pioglitazone Induces Differentiation of Primary AML Blasts Into Neutrophil Like Cells Capable of ROS Production and Phagocytosis.

Klobuch S, Steinberg T, Bruni E, Mirbeth C, Heilmeier B, Ghibelli L, Herr W, Reichle A, Thomas S.

Front Pharmacol. 2018 Nov 27;9:1380. doi: 10.3389/fphar.2018.01380. eCollection 2018.

20.

Biomarker Supervised G-CSF (Filgrastim) Response in ALS Patients.

Johannesen S, Budeus B, Peters S, Iberl S, Meyer AL, Kammermaier T, Wirkert E, Bruun TH, Samara VC, Schulte-Mattler W, Herr W, Schneider A, Grassinger J, Bogdahn U.

Front Neurol. 2018 Nov 26;9:971. doi: 10.3389/fneur.2018.00971. eCollection 2018.

21.

Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML.

Heudobler D, Klobuch S, Thomas S, Hahn J, Herr W, Reichle A.

Front Pharmacol. 2018 Nov 13;9:1279. doi: 10.3389/fphar.2018.01279. eCollection 2018.

22.

Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.

Brummer C, Faerber S, Bruss C, Blank C, Lacroix R, Haferkamp S, Herr W, Kreutz M, Renner K.

Cancer Lett. 2019 Feb 1;442:453-463. doi: 10.1016/j.canlet.2018.11.018. Epub 2018 Nov 24.

PMID:
30481565
23.

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue.

Heudobler D, Rechenmacher M, Lüke F, Vogelhuber M, Pukrop T, Herr W, Ghibelli L, Gerner C, Reichle A.

Int J Mol Sci. 2018 Nov 9;19(11). pii: E3540. doi: 10.3390/ijms19113540. Review.

24.

Non-invasive diagnosis of acute intestinal graft-versus-host disease by a new scoring system using ultrasound morphology, compound elastography, and contrast-enhanced ultrasound.

Weber D, Weber M, Hippe K, Ghimire S, Wolff D, Hahn J, Evert M, Herr W, Holler E, Jung EM.

Bone Marrow Transplant. 2019 Jul;54(7):1038-1048. doi: 10.1038/s41409-018-0381-4. Epub 2018 Nov 6.

PMID:
30401964
25.

Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience.

Schelker RC, Herr W, Reichle A, Vogelhuber M.

BMC Cancer. 2018 Oct 19;18(1):1000. doi: 10.1186/s12885-018-4885-5.

26.

Space-borne Bose-Einstein condensation for precision interferometry.

Becker D, Lachmann MD, Seidel ST, Ahlers H, Dinkelaker AN, Grosse J, Hellmig O, Müntinga H, Schkolnik V, Wendrich T, Wenzlawski A, Weps B, Corgier R, Franz T, Gaaloul N, Herr W, Lüdtke D, Popp M, Amri S, Duncker H, Erbe M, Kohfeldt A, Kubelka-Lange A, Braxmaier C, Charron E, Ertmer W, Krutzik M, Lämmerzahl C, Peters A, Schleich WP, Sengstock K, Walser R, Wicht A, Windpassinger P, Rasel EM.

Nature. 2018 Oct;562(7727):391-395. doi: 10.1038/s41586-018-0605-1. Epub 2018 Oct 17.

PMID:
30333576
27.

The conserved threonine-rich region of the HCF-1PRO repeat activates promiscuous OGT:UDP-GlcNAc glycosylation and proteolysis activities.

Kapuria V, Röhrig UF, Waridel P, Lammers F, Borodkin VS, van Aalten DMF, Zoete V, Herr W.

J Biol Chem. 2018 Nov 16;293(46):17754-17768. doi: 10.1074/jbc.RA118.004185. Epub 2018 Sep 17.

28.

Cycles of gene expression and genome response during mammalian tissue regeneration.

Rib L, Villeneuve D, Minocha S, Praz V, Hernandez N, Guex N, Herr W; CycliX Consortium.

Epigenetics Chromatin. 2018 Sep 12;11(1):52. doi: 10.1186/s13072-018-0222-0.

29.

Detrimental Effect of Broad-spectrum Antibiotics on Intestinal Microbiome Diversity in Patients After Allogeneic Stem Cell Transplantation: Lack of Commensal Sparing Antibiotics.

Weber D, Hiergeist A, Weber M, Dettmer K, Wolff D, Hahn J, Herr W, Gessner A, Holler E.

Clin Infect Dis. 2019 Apr 8;68(8):1303-1310. doi: 10.1093/cid/ciy711.

PMID:
30124813
30.

Advanced Mucinous Colorectal Cancer: Epidemiology, Prognosis and Efficacy of Chemotherapeutic Treatment.

Ott C, Gerken M, Hirsch D, Fest P, Fichtner-Feigl S, Munker S, Schnoy E, Stroszczynski C, Vogelhuber M, Herr W, Evert M, Reng M, Schlitt HJ, Klinkhammer-Schalke M, Teufel A.

Digestion. 2018;98(3):143-152. doi: 10.1159/000487710. Epub 2018 Jun 5.

PMID:
29870979
31.

Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects.

Munker S, Gerken M, Fest P, Ott C, Schnoy E, Fichtner-Feigl S, Wiggermann P, Vogelhuber M, Herr W, Stroszczynski C, Schlitt HJ, Evert M, Reng M, Klinkhammer-Schalke M, Teufel A.

BMC Cancer. 2018 Apr 23;18(1):455. doi: 10.1186/s12885-018-4380-z.

32.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
33.

The Peripheral and Intratumoral Immune Cell Landscape in Cancer Patients: A Proxy for Tumor Biology and a Tool for Outcome Prediction.

Schnell A, Schmidl C, Herr W, Siska PJ.

Biomedicines. 2018 Feb 24;6(1). pii: E25. doi: 10.3390/biomedicines6010025. Review.

34.

CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib.

Jetani H, Garcia-Cadenas I, Nerreter T, Thomas S, Rydzek J, Meijide JB, Bonig H, Herr W, Sierra J, Einsele H, Hudecek M.

Leukemia. 2018 May;32(5):1168-1179. doi: 10.1038/s41375-018-0009-0. Epub 2018 Feb 5.

PMID:
29472720
35.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

36.

Segregated hepatocyte proliferation and metabolic states within the regenerating mouse liver.

Minocha S, Villeneuve D, Rib L, Moret C, Guex N, Herr W.

Hepatol Commun. 2017 Sep 26;1(9):871-885. doi: 10.1002/hep4.1102. eCollection 2017 Nov.

37.

Pre- and post-diagnosis physical activity, television viewing, and mortality among hematologic cancer survivors.

Schmid D, Behrens G, Arem H, Hart C, Herr W, Jochem C, Matthews CE, Leitzmann MF.

PLoS One. 2018 Jan 31;13(1):e0192078. doi: 10.1371/journal.pone.0192078. eCollection 2018.

38.

In-vitro blockade of the CD4 receptor co-signal in antigen-specific T-cell stimulation cultures induces the outgrowth of potent CD4 independent T-cell effectors.

Vatter S, Schmid M, Gebhard C, Mirbeth C, Klobuch S, Rehli M, Herr W, Thomas S.

J Immunol Methods. 2018 Mar;454:80-85. doi: 10.1016/j.jim.2017.11.006. Epub 2017 Nov 14.

PMID:
29154771
39.

TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.

Schelker RC, Iberl S, Müller G, Hart C, Herr W, Grassinger J.

Hematology. 2018 Jul;23(6):337-345. doi: 10.1080/10245332.2017.1402455. Epub 2017 Nov 15.

PMID:
29140182
40.

Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial.

Walter I, Schulz U, Vogelhuber M, Wiedmann K, Endlicher E, Klebl F, Andreesen R, Herr W, Ghibelli L, Hackl C, Wiest R, Reichle A.

Med Oncol. 2017 Nov 2;34(12):192. doi: 10.1007/s12032-017-1040-0.

41.

The association between acute graft-versus-host disease and antimicrobial peptide expression in the gastrointestinal tract after allogeneic stem cell transplantation.

Weber D, Frauenschläger K, Ghimire S, Peter K, Panzer I, Hiergeist A, Weber M, Kutny D, Wolff D, Grube M, Huber E, Oefner P, Gessner A, Hehlgans T, Herr W, Holler E.

PLoS One. 2017 Sep 21;12(9):e0185265. doi: 10.1371/journal.pone.0185265. eCollection 2017.

42.

Implementation of a rapid HIT immunoassay at a university hospital - Retrospective analysis of HIT laboratory orders in patients with thrombocytopenia.

Black A, Heimerl S, Oertli L, Wilczek W, Greinacher A, Spannagl M, Herr W, Hart C.

Thromb Res. 2017 Oct;158:65-70. doi: 10.1016/j.thromres.2017.08.008. Epub 2017 Aug 15.

PMID:
28843825
43.

Potential Role of the PD-1/PD-L1 Axis in the Immune Regulation of Chronic GVHD.

Klobuch S, Weber D, Holler B, Herr W, Holler E, Wolff D.

Oncol Res Treat. 2017;40(7-8):447-450. doi: 10.1159/000471768. Epub 2017 Jun 30.

44.

Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation.

Weber D, Jenq RR, Peled JU, Taur Y, Hiergeist A, Koestler J, Dettmer K, Weber M, Wolff D, Hahn J, Pamer EG, Herr W, Gessner A, Oefner PJ, van den Brink MRM, Holler E.

Biol Blood Marrow Transplant. 2017 May;23(5):845-852. doi: 10.1016/j.bbmt.2017.02.006. Epub 2017 Feb 14.

45.

Macro- and microcirculation patterns of intrahepatic blood flow changes in patients with hereditary hemorrhagic telangiectasia.

Schelker RC, Barreiros AP, Hart C, Herr W, Jung EM.

World J Gastroenterol. 2017 Jan 21;23(3):486-495. doi: 10.3748/wjg.v23.i3.486.

46.

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.

Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dössinger G, Schiemann M, Lakshmipathi S, Martin K, Bunjes D, Harsdorf S, Weissinger EM, Menzel H, Verbeek M, Uharek L, Kröger N, Wagner E, Kobbe G, Schroeder T, Schmitt M, Held G, Herr W, Germeroth L, Bonig H, Tonn T, Einsele H, Busch DH, Grigoleit GU.

Leukemia. 2017 Oct;31(10):2161-2171. doi: 10.1038/leu.2017.16. Epub 2017 Jan 16.

PMID:
28090089
47.

Reduction of aGVHD using chicken antibodies directed against intestinal pathogens in a murine model.

Bouazzaoui A, Huber E, Dan A, Al-Allaf FA, Pfirstinger J, Sprotte G, Köstler J, Hiergeist A, Gessner A, Herr W, Holler E.

Blood. 2017 Feb 23;129(8):1052-1055. doi: 10.1182/blood-2016-06-722538. Epub 2016 Dec 23. No abstract available.

48.

Antithymocyte Globulin Induces a Tolerogenic Phenotype in Human Dendritic Cells.

Roider T, Katzfuß M, Matos C, Singer K, Renner K, Oefner PJ, Dettmer-Wilde K, Herr W, Holler E, Kreutz M, Peter K.

Int J Mol Sci. 2016 Dec 11;17(12). pii: E2081.

49.

Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset.

Bohmann EM, Fehn U, Holler B, Weber D, Holler E, Herr W, Hoffmann P, Edinger M, Wolff D.

Ann Hematol. 2017 Feb;96(2):299-310. doi: 10.1007/s00277-016-2881-x. Epub 2016 Dec 9.

PMID:
27942862
50.

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study.

Schlenk RF, Lübbert M, Benner A, Lamparter A, Krauter J, Herr W, Martin H, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Wattad M, Köhne CH, Fiedler W, Bentz M, Wulf G, Held G, Hertenstein B, Salwender H, Gaidzik VI, Schlegelberger B, Weber D, Döhner K, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group.

Ann Hematol. 2016 Dec;95(12):1931-1942. Epub 2016 Oct 3.

Supplemental Content

Support Center